Cargando…
Reduction of fibrosis and immune suppressive cells in ErbB2-dependent tumorigenesis by an LXR agonist
One of the central challenges for cancer therapy is the identification of factors in the tumor microenvironment that increase tumor progression and prevent immune surveillance. One such element associated with breast cancer is stromal fibrosis, a histopathologic criterion for invasive cancer and poo...
Autores principales: | Sheng, Gao, Yuan, Hongyan, Jin, Lu, Ranjit, Suman, Panov, Julia, Lu, Xun, Levi, Moshe, Glazer, Robert I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007044/ https://www.ncbi.nlm.nih.gov/pubmed/33780491 http://dx.doi.org/10.1371/journal.pone.0248996 |
Ejemplares similares
-
ErbBs in Lens Cell Fibrosis and Secondary Cataract
por: VanSlyke, Judy K., et al.
Publicado: (2023) -
A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016) -
APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis
por: Hong, Se-Hoon, et al.
Publicado: (2016) -
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014) -
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
por: Griffett, Kristine, et al.
Publicado: (2015)